HomeCompareAIMC vs ABBV

AIMC vs ABBV: Dividend Comparison 2026

AIMC yields 0.58% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $84.9K in total portfolio value
10 years
AIMC
AIMC
● Live price
0.58%
Share price
$61.98
Annual div
$0.36
5Y div CAGR
-48.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$0.08
Full AIMC calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — AIMC vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIMCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIMC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIMC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIMC
Annual income on $10K today (after 15% tax)
$49.37/yr
After 10yr DRIP, annual income (after tax)
$0.07/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,866.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIMC + ABBV for your $10,000?

AIMC: 50%ABBV: 50%
100% ABBV50/50100% AIMC
Portfolio after 10yr
$62.2K
Annual income
$12,862.90/yr
Blended yield
20.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AIMC
Analyst Ratings
4
Buy
7
Hold
Consensus: Hold
Price Target
$58.00
-6.4% upside vs current
Range: $58.00 — $58.00
Altman Z
2.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIMC buys
0
ABBV buys
0
No recent congressional trades found for AIMC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIMCABBV
Forward yield0.58%3.12%
Annual dividend / share$0.36$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-48.1%40.6%
Portfolio after 10y$19.8K$104.7K
Annual income after 10y$0.08$25,725.73
Total dividends collected$63.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$58.00$256.15

Year-by-year: AIMC vs ABBV ($10,000, DRIP)

YearAIMC PortfolioAIMC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,730$30.15$11,559$438.51$829.00ABBV
2$11,497$15.69$13,494$640.86$2.0KABBV
3$12,310$8.15$15,951$945.97$3.6KABBV
4$13,176$4.23$19,152$1,413.89$6.0KABBV
5$14,100$2.20$23,443$2,146.38$9.3KABBV
6$15,088$1.14$29,391$3,321.96$14.3KABBV
7$16,145$0.59$37,948$5,265.87$21.8KABBV
8$17,276$0.31$50,795$8,596.74$33.5KABBV
9$18,485$0.16$71,034$14,549.41$52.5KABBV
10$19,779$0.08$104,715$25,725.73$84.9KABBV

AIMC vs ABBV: Complete Analysis 2026

AIMCStock

Altra Industrial Motion Corp. designs, produces, and markets a range of electromechanical power transmission motion control products for use in various motion-related applications, and high-volume manufacturing and non-manufacturing processes. The company operates in two segments, Power Transmission Technologies (PTT) and Automation & Specialty (A&S). The PTT segment offers couplings, such as gear couplings, diaphragm and disc couplings, elastomeric couplings, miniature and precision couplings, universal joints, mill spindles, and shaft locking devices under the Ameridrives, Bibby, Guardian, Huco, Lamiflex, Stromag, and TB Wood's brands; clutches and brakes under the Industrial Clutch, Formsprag, Stieber, Stromag, Svendborg, Twiflex, and Wichita brands; electromagnetic clutches and brakes under the Inertia Dynamics, Matrix, Stromag, and Warner Electric brands; and gears under the Bauer Gear Motor, Boston Gear, Delroyd, and Nuttall brands. The A&S segment provides rotary precision motion solutions, including servo and stepper motors, precision linear actuators, and electronic drives and motion controllers, as well as related software under the Kollmorgen brand; and miniature motors, and motion control products, such as brush and brushless DC, can stack, and disc magnet motors under the Portescap brand. This segment also offers linear bearings, guides, glides, lead and ball screws, industrial linear actuators, resolvers, and inductors for the transition of rotary motion to linear motion under the Thomson and Nook brands. It serves in North America, the rest of Europe, Germany, China, the rest of Asia, and internationally. The company was formerly known as Altra Holdings, Inc. and changed its name to Altra Industrial Motion Corp. in November 2013. Altra Industrial Motion Corp. was incorporated in 2004 and is headquartered in Braintree, Massachusetts. As of March 27, 2023, Altra Industrial Motion Corp. operates as a subsidiary of Regal Rexnord Corporation.

Full AIMC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AIMC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIMC vs SCHDAIMC vs JEPIAIMC vs OAIMC vs KOAIMC vs MAINAIMC vs JNJAIMC vs MRKAIMC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.